Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Dementia With Lewy Bodies (DLB) Clinical Trial

Official title:
Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00776347
Study type	Interventional
Source	Osaka University
Contact
Status	Completed
Phase	N/A
Start date	October 2008
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04001517` - Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies	Phase 2
Recruiting	`NCT03030586` - ADDIA Proof-of-Performance Clinical Study
Withdrawn	`NCT04055532` - Biomarkers in Neurodegenerative Diseases
Completed	`NCT00543855` - A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)	Phase 2
Completed	`NCT01278407` - A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	Phase 3
Completed	`NCT00598650` - A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies	Phase 2